<?xml version='1.0' encoding='utf-8'?>
<document id="27049057"><sentence text="Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients."><entity charOffset="40-51" id="DDI-PubMed.27049057.s1.e0" text="indacaterol" /><entity charOffset="52-66" id="DDI-PubMed.27049057.s1.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s1.e0" e2="DDI-PubMed.27049057.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s1.e0" e2="DDI-PubMed.27049057.s1.e1" /></sentence><sentence text="Indacaterol/glycopyrronium (IND/GLY) is a fixed-dose combination (FDC) of indacaterol, an inhaled long-acting β2-agonist (LABA), and glycopyrronium, an inhaled long-acting muscarinic antagonist (LAMA), developed as a maintenance bronchodilator treatment for patients with chronic obstructive pulmonary disease (COPD)"><entity charOffset="0-11" id="DDI-PubMed.27049057.s2.e0" text="Indacaterol" /><entity charOffset="12-26" id="DDI-PubMed.27049057.s2.e1" text="glycopyrronium" /><entity charOffset="32-35" id="DDI-PubMed.27049057.s2.e2" text="GLY" /><entity charOffset="74-85" id="DDI-PubMed.27049057.s2.e3" text="indacaterol" /><entity charOffset="133-147" id="DDI-PubMed.27049057.s2.e4" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e0" e2="DDI-PubMed.27049057.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e0" e2="DDI-PubMed.27049057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e0" e2="DDI-PubMed.27049057.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e0" e2="DDI-PubMed.27049057.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e0" e2="DDI-PubMed.27049057.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e1" e2="DDI-PubMed.27049057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e1" e2="DDI-PubMed.27049057.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e1" e2="DDI-PubMed.27049057.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e1" e2="DDI-PubMed.27049057.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e2" e2="DDI-PubMed.27049057.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e2" e2="DDI-PubMed.27049057.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e2" e2="DDI-PubMed.27049057.s2.e4" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e3" e2="DDI-PubMed.27049057.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27049057.s2.e3" e2="DDI-PubMed.27049057.s2.e4" /></sentence><sentence text=" A population pharmacokinetic (PK) analysis was performed to describe the PK profiles of indacaterol and glycopyrronium following the twice daily (b"><entity charOffset="89-100" id="DDI-PubMed.27049057.s3.e0" text="indacaterol" /><entity charOffset="105-119" id="DDI-PubMed.27049057.s3.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s3.e0" e2="DDI-PubMed.27049057.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s3.e0" e2="DDI-PubMed.27049057.s3.e1" /></sentence><sentence text="i" /><sentence text="d" /><sentence text=") and once daily (o" /><sentence text="d" /><sentence text=") inhalation regimens as FDC or as monotherapies and to determine the effect of covariates" /><sentence text="" /><sentence text="PK data in 556 COPD patients were pooled from three phase 3 studies" /><sentence text=" Two phase 3 studies investigated IND/GLY 27"><entity charOffset="38-51" id="DDI-PubMed.27049057.s11.e0" text="GLY" /></sentence><sentence text="5/12" /><sentence text="5 μg b" /><sentence text="i" /><sentence text="d" /><sentence text=" and the third study investigated IND/GLY 110/50 μg o"><entity charOffset="38-40" id="DDI-PubMed.27049057.s16.e0" text="GLY" /></sentence><sentence text="d" /><sentence text=" Body weight was included in the model with fixed allometric coefficients for indacaterol and glycopyrronium"><entity charOffset="78-89" id="DDI-PubMed.27049057.s18.e0" text="indacaterol" /><entity charOffset="94-108" id="DDI-PubMed.27049057.s18.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s18.e0" e2="DDI-PubMed.27049057.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s18.e0" e2="DDI-PubMed.27049057.s18.e1" /></sentence><sentence text="" /><sentence text="Statistically significant effects of smoking, age, and sex on apparent clearance of indacaterol; smoking, and estimated glomerular filtration rate at baseline on apparent clearance and Japanese ethnicity on apparent central volume of distribution of glycopyrronium were identified"><entity charOffset="84-95" id="DDI-PubMed.27049057.s20.e0" text="indacaterol" /><entity charOffset="250-264" id="DDI-PubMed.27049057.s20.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s20.e0" e2="DDI-PubMed.27049057.s20.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s20.e0" e2="DDI-PubMed.27049057.s20.e1" /></sentence><sentence text="" /><sentence text="Systemic exposure to indacaterol and glycopyrronium was shown to be dose-proportional and time-independent following inhalation either as monotherapies or FDC"><entity charOffset="21-32" id="DDI-PubMed.27049057.s22.e0" text="indacaterol" /><entity charOffset="37-51" id="DDI-PubMed.27049057.s22.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s22.e0" e2="DDI-PubMed.27049057.s22.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s22.e0" e2="DDI-PubMed.27049057.s22.e1" /></sentence><sentence text=" None of the identified covariate effects was judged to be clinically relevant" /><sentence text=" There is no PK drug-drug interaction between indacaterol and glycopyrronium in its FDC"><entity charOffset="46-57" id="DDI-PubMed.27049057.s24.e0" text="indacaterol" /><entity charOffset="62-76" id="DDI-PubMed.27049057.s24.e1" text="glycopyrronium" /><pair ddi="false" e1="DDI-PubMed.27049057.s24.e0" e2="DDI-PubMed.27049057.s24.e0" /><pair ddi="false" e1="DDI-PubMed.27049057.s24.e0" e2="DDI-PubMed.27049057.s24.e1" /></sentence><sentence text="" /></document>